Vivus Reveals Plans To Curb Costs As Qsymia Sales Lag
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s vague corporate update includes plans to focus the Qsymia sales team on the most productive areas and potential cost-saving measures for a planned cardiovascular outcomes trial.
You may also be interested in...
Qsymia Sales Reps Recruited For Experience With Metabolic Products
Vivus will benefit from downsizing at other firms, Chief Commercial Officer Mike Miller says. The company will aggressively seek formulary coverage, expects REMS to soothe payer concerns about appropriate use of the obesity product, he notes.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.